Peptide therapy on TikTok: separating hype from human data

What did @petercamba actually say?

Peter is two weeks into taking Rybelsus (oral semaglutide) and has taken his third dose on camera. He reports losing seven pounds, reduced appetite, decreased cravings, and some nausea and wooziness after injecting. Wait, he called it a "shot" but Rybelsus is a pill. That detail matters, and we'll get to it. He also says he's eating high protein while working out, wants to "turn some of this fat into muscle," and doesn't plan to stay on it long term. His tone is cautiously optimistic, and he tells viewers "everyone reacts differently" and to "just experiment."

The general arc of his experience is consistent with how GLP-1 receptor agonists work. The specific framing, however, has some real problems worth unpacking.

Does the science back this up?

On the core effects, yes. GLP-1 receptor agonists like semaglutide are well-documented to reduce appetite and food cravings, and early weight loss in the first two to four weeks is real. Seven pounds in two weeks is on the higher end but not implausible, especially with added exercise.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed average weight loss of around 14.9% body weight over 68 weeks with injectable semaglutide. Earlier data from the PIONEER trials on oral semaglutide (Aroda et al., 2019, Lancet) showed meaningful but more modest results compared to injectable forms, largely due to absorption variability with the oral route. Nausea is the most commonly reported side effect in clinical trials, affecting up to 20% of users, particularly early in treatment. His experience tracks the known side effect profile reasonably well.

Where the science gets more complicated is the "turning fat into muscle" framing. That is not how semaglutide works, and the literature doesn't support it as a mechanism.

What did they get wrong (or right)?

He got the side effect profile right. Appetite suppression, nausea, and some light-headedness are all consistent with GLP-1 receptor agonist use, particularly in early weeks. Credit where it's due.

But there are two meaningful errors. First, he repeatedly calls Rybelsus a "shot." Rybelsus is an oral tablet, not an injection. If he is actually injecting something, that is not Rybelsus. It could be a compounded semaglutide product, a different GLP-1 medication, or something else entirely. This is not a minor mix-up because compounded peptide injectables carry different risk profiles, regulatory statuses, and dosing considerations than an FDA-approved oral tablet. Conflating them misleads viewers who may go looking for the wrong product.

Second, the phrase "turn some of this fat into muscle" is a persistent fitness myth. Fat and muscle are different tissue types. You can lose fat and gain muscle simultaneously under the right conditions, but fat does not convert into muscle. A high-protein diet plus resistance training can help preserve lean mass during GLP-1-driven weight loss, which is legitimate, but the framing here is inaccurate.

His advice to "just experiment" with a prescription medication is also a problem. These are regulated compounds with real contraindications, including a boxed warning for thyroid C-cell tumors in the semaglutide class.

What should you actually know?

Semaglutide, whether oral or injectable, is a prescription medication in a class with known, clinically significant risks. The FDA has issued warnings about thyroid tumors in animal studies, and the drug carries contraindications for people with a personal or family history of medullary thyroid carcinoma or MEN2. Nausea, vomiting, and gastrointestinal distress are common and can be severe enough to cause discontinuation.

The "short-term boost" framing also deserves scrutiny. Research shows that most patients regain significant weight after stopping GLP-1 medications. The STEP 4 trial (Rubino et al., 2021, JAMA) found that participants who discontinued semaglutide regained about two-thirds of their lost weight within a year. Going in with a defined exit plan without a maintenance strategy is a setup for a rebound.

If someone is considering semaglutide or a compounded GLP-1 peptide, the conversation starts with a licensed provider who can assess cardiovascular history, thyroid risk, and current medications. The injection-versus-pill distinction is not cosmetic. It changes bioavailability, dosing protocols, and regulatory status significantly.

• Compounded semaglutide injectables are not equivalent to FDA-approved Ozempic or Rybelsus
• GLP-1 medications require a prescription and medical supervision
• Early weight loss often includes water weight and should not be extrapolated to long-term results
• Protein intake during GLP-1 therapy is evidence-backed for preserving lean mass, per Bikou et al., 2023, Nutrients